Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

84.15 

4.18 5.2%

as of Aug 13 '20

52 Week Range:

63.41 140.36


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Apr '16 Mar '17 Apr '17 Mar '18 Mar '19 Mar '20
Equity (BVPS) 13.94
15.27
15.86
16.14
14.15
14.82
15.72
12.61
11.42
growth rate 9.5% 3.9% 1.8% -12.3% 2.3% 3.0% -19.8% -9.4%
Earnings BIT 89.50
49.90
48.19
43.06
43.73
39.21
100.28
118.34
173.83
growth rate -44.3% -3.4% -10.6% 0.8% -5.3% 155.7% 18.0% 46.9%
Avg.PE 26.88
56.18
48.54
129.12
64.57
30.80
30.80
737.79
108.63
92.38
growth rate 109.0% -13.6% 166.0% -29.3% -52.3% 0.0% 2,295.4% -85.3% -15.0%
ROA 7.67
3.27
2.36
1.13
-3.96
-2.05
3.68
4.38
6.02
growth rate -57.4% -27.8% -52.1% -100.0% 0.0% 100.0% 19.0% 37.4%
ROE 9.43
5.17
4.37
2.03
-7.18
-3.60
6.11
7.75
12.20
growth rate -45.2% -15.5% -53.6% -100.0% 0.0% 100.0% 26.8% 57.4%
ROIC 9.37
3.91
3.62
1.78
-4.19
-2.41
4.76
6.17
8.87
growth rate -58.3% -7.4% -50.8% -100.0% 0.0% 100.0% 29.6% 43.8%
Cur. Ratio 4.03
3.31
2.87
3.02
2.63
2.42
1.35
2.44
2.20
growth rate -17.9% -13.3% 5.2% -12.9% -4.1% -25.3% 80.7% -9.8%
Quick Ratio 2.79
1.94
1.64
1.62
1.47
1.38
0.86
1.50
1.10
growth rate -30.5% -15.5% -1.2% -9.3% -3.1% -21.1% 74.4% -26.7%
Leverage 1.24
1.90
1.81
1.80
1.83
1.67
1.64
1.91
2.16
growth rate 53.2% -4.7% -0.6% 1.7% -4.5% -0.9% 16.5% 13.1%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Apr '16 Mar '17 Apr '17 Mar '18 Mar '19 Mar '20
Acct.Receivable 145.13
183.89
164.60
145.83
157.09
152.68
151.23
185.03
165.21
growth rate 26.7% -10.5% -11.4% 3.8% -1.4% -1.0% 22.4% -10.7%
Acct.Payable 72.95
99.64
53.56
48.43
39.67
42.97
55.27
63.36
50.73
growth rate 36.6% -46.3% -9.6% -9.5% 4.1% 28.6% 14.7% -19.9%
Cur.Assets 527.13
597.01
622.98
557.67
488.09
510.03
521.18
576.12
603.64
growth rate 13.3% 4.4% -10.5% -6.5% 2.2% 2.2% 10.5% 4.8%
Total Assets 911.14
1,461.92
1,514.18
1,485.42
1,319.13
1,238.71
1,237.34
1,274.77
1,267.11
growth rate 60.5% 3.6% -1.9% -5.8% -3.1% -0.1% 3.0% -0.6%
Cash 228.86
179.12
192.47
160.66
115.12
139.56
180.17
169.35
137.31
growth rate -21.7% 7.5% -16.5% -15.4% 10.1% 29.1% -6.0% -18.9%
Inventory 117.16
183.78
197.66
211.08
187.03
176.93
160.80
194.34
270.28
growth rate 56.9% 7.6% 6.8% -5.9% -2.7% -9.1% 20.9% 39.1%
Cur.Liabilities 130.74
180.14
216.93
188.68
185.55
211.18
384.70
235.76
274.82
growth rate 37.8% 20.4% -13.0% -0.8% 6.7% 82.2% -38.7% 16.6%
Liabilities 178.50
692.74
676.29
659.30
597.56
499.10
484.91
606.90
680.00
growth rate 288.1% -2.4% -2.5% -4.8% -8.6% -2.8% 25.2% 12.1%
LT Debt 2.88
456.94
392.06
406.37
364.53
253.63
59.42
322.45
314.99
growth rate 15,782.7% -14.2% 3.7% -5.3% -16.6% -76.6% 442.6% -2.3%
Equity 732.63
769.18
837.89
826.12
721.57
739.61
752.43
667.87
587.11
growth rate 5.0% 8.9% -1.4% -6.5% 1.2% 1.7% -11.2% -12.1%
Common Shares 52.00
52.00
52.00
52.00
51.00
52.00
54.00
53.00
52.00
growth rate 0.0% 0.0% 0.0% -1.0% 2.0% 1.9% -1.9% -1.9%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Apr '16 Mar '17 Apr '17 Mar '18 Mar '19 Mar '20
Capital Expenditures 53.20
62.19
73.65
122.22
102.41
76.14
74.80
118.96
48.76
growth rate 16.9% 18.4% 66.0% -8.5% -13.8% -1.8% 59.0% -59.0%
Cash Dividends 0.00 0.00
growth rate
Cash From OA 115.32
85.07
139.52
127.18
121.87
159.74
220.35
159.28
158.22
growth rate -26.2% 64.0% -8.9% -2.1% 14.5% 37.9% -27.7% -0.7%
FCF per Share 1.25
0.49
1.14
-0.14
0.55
1.74
2.39
1.35
1.55
growth rate -60.8% 132.7% -100.0% 100.0% 77.9% 17.2% -43.5% 14.8%
Sale Purchase of Stock -30.80
-18.34
20.45
14.05
18.37
33.00
40.34
growth rate 0.0% 100.0% -31.3% 14.3% 34.0% 22.3%
FCF 62.00
23.00
66.00
5.00
19.00
19.46
84.00
83.60
146.00
40.00
109.00
growth rate -62.9% 187.0% -92.4% 280.0% 2.4% 331.7% -0.5% 74.6% -72.6% 172.5%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Apr '16 Mar '17 Apr '17 Mar '18 Mar '19 Mar '20
Sales 727.84
891.99
938.51
910.37
908.83
886.12
903.92
967.58
988.48
growth rate 22.6% 5.2% -3.0% -0.1% -1.3% 2.0% 7.0% 2.2%
Op.Income 66.89
38.80
48.19
43.06
43.73
39.21
100.28
118.34
173.83
growth rate -42.0% 24.2% -10.6% 0.8% -5.3% 155.7% 18.0% 46.9%
IBT 89.50
49.90
36.40
31.17
-53.42
-27.48
59.63
73.63
87.15
growth rate -44.3% -27.1% -14.4% -100.0% 0.0% 100.0% 23.5% 18.4%
Net Income 66.89
38.80
35.15
16.90
-55.58
-26.27
45.57
55.02
76.53
growth rate -42.0% -9.4% -51.9% -100.0% 0.0% 100.0% 20.7% 39.1%
EPS 1.30
0.74
0.67
0.32
-1.09
-0.51
0.85
1.04
1.48
growth rate -43.1% -9.5% -52.2% -100.0% 0.0% 100.0% 22.4% 42.3%
Gross Profit 369.24
428.13
468.37
434.42
405.91
378.49
412.63
440.01
487.82
growth rate 16.0% 9.4% -7.3% -3.3% -3.4% 9.0% 6.6% 10.9%
R&D 36.80
44.39
54.20
54.19
44.97
37.56
34.55
34.97
30.00
growth rate 20.6% 22.1% 0.0% -8.9% -8.6% -8.0% 1.2% -14.2%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 36.48
53.50
43.40
42.96
growth rate 46.7% -18.9% -1.0%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 163.34
176.54
170.75
165.21
141.09
growth rate 8.1% -3.3% -3.3% -14.6%
Acct.Payable 60.79
57.45
52.30
50.73
48.46
growth rate -5.5% -9.0% -3.0% -4.5%
Cur.Assets 615.28
567.79
582.58
603.64
759.41
growth rate -7.7% 2.6% 3.6% 25.8%
Total Assets 1,259.61
1,190.54
1,237.75
1,267.11
1,433.17
growth rate -5.5% 4.0% 2.4% 13.1%
Cash 190.23
112.03
126.42
137.31
275.73
growth rate -41.1% 12.8% 8.6% 100.8%
Inventory 221.95
244.50
254.17
270.28
294.51
growth rate 10.2% 4.0% 6.3% 9.0%
Cur.Liabilities 293.67
240.07
256.69
274.82
407.83
growth rate -18.3% 6.9% 7.1% 48.4%
Liabilities 668.64
606.79
663.17
680.00
growth rate -9.3% 9.3% 2.5%
LT Debt 318.14
313.98
309.74
314.99
296.89
growth rate -1.3% -1.4% 1.7% -5.7%
Equity 590.97
583.75
574.58
587.11
608.57
growth rate -1.2% -1.6% 2.2% 3.7%
Common Shares 0.51
0.51
0.50
0.50
0.51
growth rate -0.4% -0.4% -0.2% 0.8%
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 8.25
9.47
20.39
10.65
growth rate 14.8% 115.2% -47.8%
Cash Dividends
growth rate
Cash From OA 2.63
29.90
79.28
46.41
growth rate 1,037.8% 165.2% -41.5%
Sale Purchase of Stock
growth rate
FCF -5.62
20.43
58.89
35.76
growth rate 100.0% 188.3% -39.3%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 238.45
252.57
258.97
238.49
growth rate 5.9% 2.5% -7.9%
Op.Income 36.48
53.50
43.40
42.96
growth rate 46.7% -18.9% -1.0%
IBT -17.73
45.09
37.83
21.96
growth rate 100.0% -16.1% -42.0%
Net Income -8.48
37.49
29.90
17.62
growth rate 100.0% -20.3% -41.1%
EPS
growth rate
Gross Profit 115.91
127.28
128.05
116.42
growth rate 9.8% 0.6% -9.1%
R&D 7.49
6.87
6.86
8.80
growth rate -8.3% -0.1% 28.2%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

E (24.69)

YOY Growth Grade:

F (13.08)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 43.05 45.41 21.33
EPS / Growth 12.0% 1.85 12.0%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 8.3% 8.3%
Future PE 2.00 27.01 27.01
Future EPS 2.05 4.12 4.12
Value Price
MOS %
1.01
-98.8%
27.54
-67.3%
27.54
-67.3%
MOS Price 0.51 13.77 13.77
IRT 37.32 18.77 18.77

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.